Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer.

Cancer research communications - 1 Sept 2025

Yaeger Rona, Martini Jean-François, Pasquina Lincoln, Tunquist Brian, Zhang Xiaosong, Kaiser Fatima, Pantoja Galicia Norberto, Deng Shibing, Gong Siliang, Guo Cui, Kiely Jimmy, Ng Ta-Chou Vincent, Ferrier Graham, Tabernero Josep, Kopetz Scott

Abstract excerpt

PURPOSE: The BRAF inhibitor encorafenib (Enco) plus the anti-EGFR antibody cetuximab (Cetux) improved overall survival, objective response rate, and progression-free survival in previously treated BRAFV600E-mutant metastatic colorectal cancer in BEACON, a phase III randomized trial, leading to regulatory approval for this indication. To support rapid, plasma-based testing for BRAFV600E identification, clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Circulating Tumor DNA

Share to Colorectal Neoplasms

Share to Liquid Biopsy

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 40832988
DOI: 10.1158/2767-9764.CRC-25-0002
PMCID: PMC12417970

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer.PMID 40832988Read ↗

Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.Semantic proximity Read ↗

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy SamplesSemantic proximity Read ↗

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.Semantic proximity Read ↗

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial.Semantic proximity Read ↗

Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer.Semantic proximity Read ↗

Clinical performance evaluation of a highly sensitive Safe-SeqS plasma circulating-tumor DNA assay for the detection of RAS and BRAF V600E mutations in metastatic colorectal cancerSemantic proximity Read ↗

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinibSemantic proximity Read ↗

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.Semantic proximity Read ↗

[Detection of BRAF V600E mutation in metastatic colorectal carcinoma : A QuIP round robin test].Semantic proximity Read ↗

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.